NICE International, National Institute for Health and Clinical Excellence, London, UK.
Pharmacoeconomics. 2010;28(10):799-811. doi: 10.2165/11535260-000000000-00000.
Health systems that have fixed budgets and a coherent organizational structure generally have found it valuable to have a dedicated primary research capacity to answer decision-oriented value-for-money questions of particular importance to the system. The UK NHS is one example of such a system. Here, we review the historical evolution of building comparative effectiveness research (CER) capacity in the NHS, describe the current situation, with a focus on how this research is used to inform decisions, and discuss present and emerging challenges. We draw some possible lessons for the US, which is currently considering using CER to inform healthcare policy and practice decisions.
通常情况下,拥有固定预算和连贯组织结构的医疗体系会发现,建立专门的基础研究能力来回答对该体系特别重要的决策型投入产出比问题是很有价值的。英国国民保健制度(NHS)就是这样一个体系。在这里,我们回顾了在英国国民保健制度中建立比较效益研究(CER)能力的历史演变,描述了当前的情况,重点介绍了如何利用这项研究来为决策提供信息,并讨论了当前和新出现的挑战。我们为美国汲取了一些可能的经验教训,美国目前正在考虑利用 CER 为医疗保健政策和实践决策提供信息。